title: Stakeholder engagement for the New Zealand Atlas of Healthcare Variation: cardiovascular disease secondary prevention: VIEW-3.
abstract: OBJECTIVE
  As part of the Health Quality and Safety Commission's Atlas of Healthcare Variation in New Zealand, sociodemographic and regional differences in drug management for people with cardiovascular disease (CVD) were mapped. The aim of stakeholder engagement was to obtain feedback regarding interpretation, presentation and use of the Atlas data.
  
  
  METHODS
  Feedback was obtained through surveys, one-on-one interviews and presentations at various meetings of clinicians, managers and researchers with an interest in CVD. Presentation and utility of the Atlas data for frontline quality improvement was explored.
  
  
  RESULTS
  28 stakeholders completed one-on-one feedback and over 100 attended meetings where the Atlas data were presented. Differences in dispensing by medication type, age, gender and ethnicity were thought to be related to diagnostic accuracy or the behaviour of prescribers or patients. Stakeholders found a funnel plot of the variation in triple therapy dispensing among general practices to be the most useful method of presentation, as it enabled practitioners to benchmark against peers, highlight areas for improvement, and monitor their progress over time.
  
  
  CONCLUSIONS
  Stakeholder engagement has informed the interpretation of findings and the formatting of the Atlas data in a way that would potentially lead to improvements in the quality of patient care.
authors.affiliation: Section of Epidemiology and Biostatistics, School of Population Health, University of Auckland, PO Box 92019, Auckland, New Zealand. c.grey@auckland.ac.nz.
authors.forename: Corina
authors.initials: C
authors.lastname: Grey
authors.forename: Sue
authors.initials: S
authors.lastname: Wells
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Exeter
authors.forename: Grant
authors.initials: G
authors.lastname: Hanham
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Zhao
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Kerr
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001271:Atlases as Topic; D019985:Benchmarking; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D016208:Databases, Factual; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D004359:Drug Therapy, Combination / Q000706:statistics & numerical data; D005006:Ethnicity / Q000706:statistics & numerical data; D005246:Feedback; D005260:Female; D054624:Health Status Disparities; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D017063:Outcome Assessment, Health Care; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D058996:Quality Improvement; D055502:Secondary Prevention / Q000458:organization & administration*; D017678:Sex Distribution; D012984:Software
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors